v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities    
Net loss $ (21,529) $ (24,061)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 283 325
Stock-based compensation 3,294 3,198
Change in fair value of warrant liability (102) 337
Non-cash change in fair value of term loan 256 (247)
Non-cash lease expense 339 325
Other (5) 27
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (1,052) (693)
Accounts payable 923 3,980
Accrued expenses and other liabilities (2,125) 422
Deferred revenue (2,302) (3,411)
Net cash used in operating activities (22,020) (19,798)
Cash flows from investing activities    
Purchase of research and development license (378) (140)
Other 7  
Net cash used in investing activities (371) (140)
Cash flows from financing activities    
Debt issuance costs for term loan   (18)
Payment of shelf registration costs (47)  
Proceeds from common stock issuances under ESPP 75 26
Other (80) (30)
Net cash used in financing activities (52) (22)
Net decrease in cash, cash equivalents and restricted cash (22,443) (19,960)
Cash, cash equivalents and restricted cash at the beginning of the period 141,636 146,540
Cash, cash equivalents and restricted cash at the end of the period 119,193 126,580
Cash and cash equivalents 116,593 123,980
Restricted cash 2,600 2,600
Supplemental disclosure of cash flow information:    
Cash paid for interest 1,294 1,329
Supplemental disclosure of noncash investing and financing activities:    
Property, plant and equipment in accounts payable and accrued expenses   $ 52
Offering costs not yet paid $ 23